BR112012028726A2 - métodos de complexação de ciclodextrima para a formulação de inibidores proteassoma de peptídeos - Google Patents

métodos de complexação de ciclodextrima para a formulação de inibidores proteassoma de peptídeos

Info

Publication number
BR112012028726A2
BR112012028726A2 BR112012028726A BR112012028726A BR112012028726A2 BR 112012028726 A2 BR112012028726 A2 BR 112012028726A2 BR 112012028726 A BR112012028726 A BR 112012028726A BR 112012028726 A BR112012028726 A BR 112012028726A BR 112012028726 A2 BR112012028726 A2 BR 112012028726A2
Authority
BR
Brazil
Prior art keywords
cyclodextrime
formulation
proteasome inhibitors
peptide proteasome
methods
Prior art date
Application number
BR112012028726A
Other languages
English (en)
Other versions
BR112012028726B1 (pt
Inventor
Evan Lewis
Mouhannad Jumaa
Peter Shwonek
Sean Dalziel
Original Assignee
Onyx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49549072&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012028726(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Onyx Therapeutics Inc filed Critical Onyx Therapeutics Inc
Publication of BR112012028726A2 publication Critical patent/BR112012028726A2/pt
Publication of BR112012028726B1 publication Critical patent/BR112012028726B1/pt

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

métodos de complexação de ciclodextrima para a formulação de proteassoma de peptídeos.a presente divulgação fornece métodos para a formulação de composições que compreendem um ou mais inibidores de proteassoma de peptídeo e uma ciclodextrina,com particularidade uma ciclodextrina substituida.estes métodos aumentam substancialmente a solubilidade e estabilidade destes inibidores de proteassoma e facilitam tanto a sua fabricação quanto a sua administração.
BR112012028726-5A 2012-05-08 2012-09-13 Método para preparar uma composição farmacêutica com baixo teor de cloreto BR112012028726B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261644122P 2012-05-08 2012-05-08
US61/644,122 2012-05-08
PCT/US2012/055127 WO2013169282A1 (en) 2012-05-08 2012-09-13 Cylodextrin complexation methods for formulating peptide proteasome inhibitors

Publications (2)

Publication Number Publication Date
BR112012028726A2 true BR112012028726A2 (pt) 2016-07-19
BR112012028726B1 BR112012028726B1 (pt) 2021-07-13

Family

ID=49549072

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012028726-5A BR112012028726B1 (pt) 2012-05-08 2012-09-13 Método para preparar uma composição farmacêutica com baixo teor de cloreto

Country Status (21)

Country Link
US (2) US20130303465A1 (pt)
JP (1) JP2015516416A (pt)
KR (1) KR20150007361A (pt)
CN (1) CN103781490A (pt)
AR (2) AR087863A1 (pt)
AU (1) AU2012238318B2 (pt)
BR (1) BR112012028726B1 (pt)
CA (1) CA2793894A1 (pt)
CO (1) CO6571868A2 (pt)
CR (1) CR20120485A (pt)
CU (1) CU20120159A7 (pt)
DO (1) DOP2012000252A (pt)
EA (1) EA201201519A1 (pt)
EC (1) ECSP12012167A (pt)
MA (1) MA35238B1 (pt)
MX (1) MX2012010891A (pt)
MY (2) MY196510A (pt)
SG (1) SG194417A1 (pt)
TW (1) TWI603737B (pt)
WO (1) WO2013169282A1 (pt)
ZA (1) ZA201207384B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
DK2814849T3 (da) 2012-02-15 2020-03-09 Cydex Pharmaceuticals Inc Fremgangsmåde til fremstilling af cyclodextrin-derivater
AR095426A1 (es) 2013-03-14 2015-10-14 Onyx Therapeutics Inc Inhibidores tripeptídicos de la epoxicetona proteasa
DK2970225T3 (en) 2013-03-14 2018-09-24 Onyx Therapeutics Inc DIPEPTIDE AND TRIPEPTIDE AS EPOXY-KETONE PROTEASE INHIBITORS
GB201312737D0 (en) 2013-07-17 2013-08-28 Univ Greenwich Cyclodextrin
WO2015009888A2 (en) 2013-07-19 2015-01-22 Onyx Therapeutics, Inc. Peptide epoxyketone proteasome inhibitors in combination with pim kinase inhibitors for treatment of cancers
CN104945470B (zh) * 2014-03-30 2020-08-11 浙江大学 杂环构建的三肽环氧酮类化合物及制备和应用
CN103936828A (zh) * 2014-05-12 2014-07-23 苏州科耐尔医药科技有限公司 卡非佐米中间体及卡非佐米的制备方法
CN105919972A (zh) * 2015-12-18 2016-09-07 重庆两江药物研发中心有限公司 一种包载卡非佐米的纳米粒制剂及其制备方法
TWI759301B (zh) * 2016-05-24 2022-04-01 美商安美基公司 聚乙二醇化卡非佐米化合物
UA125648C2 (uk) 2016-08-05 2022-05-11 Емджен Інк. Синтез (s)-2-аміно-4-метил-1-((r)-2-метилоксиран-2-іл)-пентан-1-ону та його фармацевтично прийнятних солей
WO2018038687A1 (en) 2016-08-22 2018-03-01 Mustafa Nevzat Ilaç Sanayii A.Ş. Pharmaceutical formulations comprising a bortezomib-cyclodextrin complex
US20180282260A1 (en) * 2017-03-31 2018-10-04 Valent Biosciences Llc 1-aminocyclopropane-1-carboxylic acid polymorphs
US10975121B2 (en) 2017-06-24 2021-04-13 Cytogel Pharma, Llc Analgesic mu-opioid receptor binding peptide pharmaceutical formulations and uses thereof
CN111344018A (zh) 2017-11-16 2020-06-26 美国安进公司 聚乙二醇化卡非佐米化合物的稳定的组合物
EP3716948B1 (en) * 2017-11-30 2023-11-22 Cytogel Pharma, LLC Novel analgesic pharmaceutical formulations and uses thereof
AU2021292417A1 (en) * 2020-06-19 2023-01-19 Amgen Inc. Methods of measuring carfilzomib
US11246874B1 (en) 2021-04-20 2022-02-15 Oxygen Biotech LLC Treatment of COVID-19

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE499109T1 (de) * 2004-12-07 2011-03-15 Proteolix Inc Zusammensetzung zur proteasomhemmung
KR101274417B1 (ko) * 2005-11-09 2013-06-17 프로테올릭스, 인코퍼레이티드 효소 저해를 위한 화합물
MY173938A (en) * 2007-10-04 2020-02-27 Onyx Therapeutics Inc Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides

Also Published As

Publication number Publication date
SG194417A1 (en) 2013-12-30
MA35238B1 (fr) 2014-07-03
EA201201519A1 (ru) 2013-11-29
AR087863A1 (es) 2014-04-23
AU2012238318A1 (en) 2013-11-28
AR127861A2 (es) 2024-03-06
TW201345543A (zh) 2013-11-16
ECSP12012167A (es) 2013-02-28
CO6571868A2 (es) 2012-11-30
CN103781490A (zh) 2014-05-07
US20130303465A1 (en) 2013-11-14
MY196510A (en) 2023-04-18
MY165002A (en) 2018-02-28
BR112012028726B1 (pt) 2021-07-13
ZA201207384B (en) 2018-12-19
WO2013169282A1 (en) 2013-11-14
US20130303482A1 (en) 2013-11-14
CR20120485A (es) 2013-12-18
NZ602490A (en) 2016-03-31
KR20150007361A (ko) 2015-01-21
CU20120159A7 (es) 2014-03-26
MX2012010891A (es) 2014-03-05
DOP2012000252A (es) 2013-12-31
JP2015516416A (ja) 2015-06-11
AU2012238318B2 (en) 2014-02-13
TWI603737B (zh) 2017-11-01
CA2793894A1 (en) 2013-11-08

Similar Documents

Publication Publication Date Title
BR112012028726A2 (pt) métodos de complexação de ciclodextrima para a formulação de inibidores proteassoma de peptídeos
CY1122786T1 (el) Δοσολογικα σχηματα για ενωσεις κατηγοριας εχινοκανδινης
CR20150228A (es) Inhibidores de la tirosina-quinasa de bruton
BR112018010720A2 (pt) agonistas do receptor de apelina e métodos de uso
CU20170172A7 (es) 4,6-diaminoquinolin-3-carbonitrilos sustituidos útiles como agentes analgésicos, antipiréticos o antiinflamatorios y antineoplásicos
CL2013003145A1 (es) Formulación farmacéutica que comprende mezcla de anticuerpo anti-alfa4beta7, un antioxidante o quelante y al menos un aminoácido libre.
BR112016024631A2 (pt) cápsulas antimicrobianas para conectores médicos
UY34698A (es) Combinaciones farmacéuticas que comprenden un análogo de tionucleótidos
BR112015019985A2 (pt) Novo análogo de insulina e sua utilização
BR112013007362A2 (pt) composição farmacêutica
CY1123056T1 (el) Νεα μορφη χορηγησης της ρασεκαδοτριλης
BR112016008736A2 (pt) formulação estável de insulina glulisina
BR112015031278A8 (pt) compostos e nanopartículas de platina com base em lipídio
BR112015001414A2 (pt) composição antideriva
ECSP16062173A (es) Derivados de ácido heteroaril butanóico como inhibidores de lta4h
BR112018011526A2 (pt) compostos policíclicos como inibidores da tirosina quinase de bruton
BR112015030268A2 (pt) composição farmacêutica, recipiente, kit, e, método para a preparação de uma composição
CO6650346A2 (es) Composiciones de tetraciclina
TN2013000373A1 (en) Pharmaceutical formulation comprising inositol
AU2018253594A1 (en) Dihydroxyphenyl neurotransmitter compounds, compositions and methods
MX2019012375A (es) Formulaciones del inhibidor del antigeno-1 asociado a la funcion de linfocitos (lfa-1).
CY1119984T1 (el) Σταθεροποιημενη αμορφη μορφη αγομελατινης, μια μεθοδος για την παρασκευη της και φαρμακευτικες συνθεσεις που την περιεχουν
CY1118277T1 (el) Σταθερη φαρμακοτεχνικη μορφη πεξιγανανης
WO2012142256A3 (en) Modulators of mitochondrial protein import
BR112013027391A2 (pt) formulação farmacêutica, frasco e kit

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/09/2012, OBSERVADAS AS CONDICOES LEGAIS.

B17A Notification of administrative nullity (patentee has 60 days time to reply to this notification)

Free format text: REQUERENTE DA NULIDADE: NATCOFARMA DO BRASIL LTDA - 870220003378 - 13/1/2022

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI NO 52402.009270/2022-71 ORIGEM: 31A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO: 5062152-58.2022.4.02.5101/RJ NULIDADE DA PATENTE DE INVENCAO COM PEDIDO DE ANTECIPACAO DE TUTELA AUTOR: NATCOFARMA DO BRASIL LTDA. REU(S): ONYX THERAPEUTICS, INC. E INPI-INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL